Skip to content

Advertisement

Chinese Neurosurgical Journal

What do you think about BMC? Take part in

Open Access

Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature

  • Meng Zhu1, 2,
  • Chen Zhang2,
  • Kai Zhao3,
  • Leilei Wang4,
  • Jian Sun2,
  • Yugong Feng1,
  • Weicheng Yao1,
  • Shizhu Yu5,
  • Cuiyun Sun5 and
  • Xuejun Yang2Email author
Chinese Neurosurgical Journal20173:22

https://doi.org/10.1186/s41016-017-0087-2

Received: 24 January 2017

Accepted: 19 June 2017

Published: 8 August 2017

Abstract

Background

Pleomorphic xanthoastrocytoma (PXA) is usually considered a relatively benign and localized entity. However, cases of PXA with anaplastic features have been reported in recent years. Anaplastic pleomorphic xanthoastrocytoma has been added to the 2016 WHO classification of CNS tumors as a distinct entity.

Case presentation

We describe a rare case of PXA with dissemination, both at the time of diagnosis and after treatment. The 20-year-old male presented with signs of high intracranial pressure and sudden-onset transient seizures. Imaging examinations showed diffuse lesions widely distributed in the left hemisphere, and on histopathological examination, he was diagnosed with anaplastic PXA. The patient underwent surgical treatment and adjuvant concurrent chemoradiation. Follow-up MRI revealed early recurrence and distant spread of the tumor.

Conclusions

Anaplastic PXA usually has unique characteristics, including dissemination, early recurrence, and chemoresistance. A strategy based on early diagnosis and aggressive treatment is warranted. However, sufficiently powered studies are required to generate evidence-based guidelines.

Keywords

Anaplastic pleomorphic xanthoastrocytomaDisseminationTreatment

Background

Pleomorphic xanthoastrocytoma (PXA), first described by Kappes et al., is a rare tumor accounting for less than 1% of all astrocytic tumors [1]. PXA predominantly affects young patients and frequently presents with a history of chronic epilepsy. The lesion mainly appears in the cerebral hemispheres, especially the temporal lobe [2]. PXA usually has a benign biological behavior and is typically associated with a good prognosis [2, 3]. However, cases of PXA with anaplastic features have been reported recently [2, 47]. Anaplastic PXA, WHO grade III, has been added to the 2016 WHO classification of CNS tumors as a distinct entity [8]. Patients with anaplastic PXA have shorter survival than patients with conventional PXA. Here, we report the case of a student who had anaplastic PXA with a disseminated growth pattern, both at the time of diagnosis and after comprehensive therapy.

Case presentation

A 20-year-old male patient was admitted to the hospital with a history of nausea, vomiting and headache since 2 days, and sudden-onset transient seizure since 2 h. Ten years ago, the patient sustained an epileptic seizure and brain Magnetic Resonance Imaging revealed no abnormalities. The symptoms improved with standard medical treatment. Physical examination at admission was unremarkable. CT-scan revealed an ill-defined lesion in the right temporal lobe. On MRI, the lesion was found to be widely distributed in the temporal, frontal, parietal, occipital, and insular lobes of the left hemisphere. The lesion was hypointense on T1 images, hyperintense on T2 and T2Flair images, and a mild localized enhancement on gadolinium (Gd)-enhanced images (Fig. 1a-d). Positron emission tomography–computed tomography (PET-CT) demonstrated intense 18F–fluorodeoxyglucose (FDG) and 11C–methionine (MET) uptake in the left temporal lesion, suggesting an aggressive neoplasm (Fig. 1e and f). The area of tumor on MET images exceeded T2Flair, and likely reflected the invasion front of the tumor.
Fig. 1

MRI and PET-CT imaging findings. The lesion was hypointense on T1-weighted image (a), hyperintense on T2-weighted image (b) and T2Flair image (c) with mild localized enhancement on Gd-enhanced image (d). MET-PET showing localized high accumulation in the left temporal lesion (e). FDG-PET showing localized high accumulation in the left temporal lesion (f)

The preoperative diagnosis appeared to be diffuse astrocytoma or a high grade glioma. A standard left frontal-temporal craniotomy was performed using multimodal image fusion guided navigation and intraoperative MRI technology. The boundary of the tumor was not clear and subtotal tumor resection was performed.

Histopathological examination revealed anaplastic PXA (WHO grade III). Tumor cells were pleomorphic and spindle with abundant pink cytoplasm, and were arranged in a fascicular pattern (Fig. 2a). Many cells had a lipid-filled, foamy cytoplasm interspersed between other cells that had bizarre nuclei, occasionally multinucleated (Fig. 2b). Immunohistochemical staining was positive for glial fibrillary acidic portein (GFAP) (Fig. 2c), S100, vimentin. However, there was a negative expression of O-6-methylguanine DNA methyltransferase (MGMT), MDR-1, TP53, and CD34. The Ki-67 labeling index was 10.70% (Fig. 2d). No signs of necrosis were observed.
Fig. 2

Photomicrographs of tumor specimens. Photomicrographs of hematoxylin and eosin – stained sections of tumor specimens (×100) (a). Pleomorphic cells with abundant pink, foamy, lipid-filled cytoplasm and multiangular nuclei (×400) (b). Positive expression of GFAP (c). Ki-67 labeling index was 10.7% (d)

Postoperative images showed tumor residue that was not amenable to operative removal (Fig. 3a). The patient had no obvious dysfunction and received adjuvant concurrent chemoradiation 20 days after the surgery. Temozolamide (TMZ, 75 mg/m2) was administered during radiotherapy, and subsequent chemotherapy cycles of 5 days every 28 days were administered. Three months after surgery, repeat Gd-enhanced MRI showed enhanced lesions around the surgical residual cavity and the left lateral ventricular trigone (Fig. 3b). It was more like pseudoprogression than tumor recurrence. After an observation period of 3 months, the volume of enhanced lesions was found to have increased (Fig. 3c). Therefore, TMZ (150 mg/m2) combined with cisplatin (50 mg/m2 for 2 days) was administered for one cycle. After 6 cycles, MRI showed a decrease in the volume of enhanced lesions, but with concomitant findings of leptomeningeal infiltration around the brainstem and cerebellum (Fig. 3d). Finally, one new enhanced solid lesion appeared in the left frontal lobe at 11 months after the surgery (Fig. 3e). T2Flair images revealed that the tumor cells might even have invaded the opposite hemisphere through white matter fibers (Fig. 3f). The patient died of tumor progression 18 months after the surgery.
Fig. 3

Follow-up MRI study after the operation. T2Flair image immediately after the operation (a). Gd-enhanced image 3 months after the operation (b). Gd-enhanced image 6 months after the operation (c). Gd-enhanced image 8 months after the operation, arrow: leptomeningeal infiltration (d). Gd-enhanced image 11 months after the operation, arrow: distant spread to the frontal lobe. (e). T2Flair image 12 months after the operation (f)

Discussion

PXA is identified as grade II according to the 2007 WHO classification of CNS tumors, and is therefore considered a relatively benign type [9]. Surgical excision is the preferred treatment option and is usually effective. However, some PXAs have been reported to exhibit anaplastic features. The term “PXA with anaplastic features” was proposed in 1999 [2]. A diagnosis of PXA with anaplastic features is usually based on their histological characteristics and the typical molecular characteristics. Giannini et al. [2] proposed criteria for the diagnosis of PXA with anaplastic features, i.e., high mitotic activity (five or more mitoses per 10 HPF) with or without necrosis. However, many other factors need to be considered in order to standardize the diagnosis and treatment of PXA with anaplastic features. Hirose et al. [10] suggested that necrosis, microvascular proliferation, marked cellular anaplasia, and high Ki-67 index, are also indicative of PXA with anaplastic features. Finally, anaplastic PXA, was added to the 2016 WHO classification of CNS tumors as WHO grade III, instead of the descriptive title of “PXA with anaplastic features”. In the current case, Ki-67 labeling index was as high as 10.70%. The patient met the criteria for the diagnosis of anaplastic PXA.

The conventional PXA usually presents as a localized mass which is isointense on T1 images, hyperintense on T2 images, and heterogeneously enhanced. And the mass tends to contain both a solid nodulation and a cystic component. However, anaplastic PXA may manifest very different features on imaging. Different forms of dissemination at the time of diagnosis or after treatment have been documented. Lubansu A et al. [11] reported a 7-year-old girl with anaplastic PXA, with craniospinal meningeal dissemination at the time of diagnosis. Benjamin et al. [6] reported a case of a 65-year-old man with anaplastic PXA and spinal leptomeningeal spread at the time of diagnosis. In another case, multiple nodular lesions appeared throughout the CNS after surgery in a 47-year-old woman with anaplastic PXA [5]. In our case, the tumor did not present typical radiologic characteristics. There was no cystic component, and tumor dissemination was observed both at the time of diagnosis and after therapy. The tumor invaded multiple lobes and was mistaken for a diffuse astrocytoma prior to the operation. Despite aggressive treatment, the tumor recurred early and spread to distant sites. Whether anaplastic PXA has a stronger ability to invade and disseminate than that of a conventional PXA is a subject of debate. We suggest that PXA with dissemination, early recurrence, or resistance to adjuvant therapy should be treated as anaplastic PXA.

A sound understanding of the bio-molecular characteristics is critical to the development of tumor therapeutics. Unlike some low grade gliomas and high grade gliomas, very few researches have focused on the molecular biological features of PXA. Based on the present findings, anaplastic PXA do manifest some distinctive characteristics.

Genetic testing for the BRAF V600E mutation may help differentiate PXA from other astrocytic tumors, since the latter almost always lack this mutation [12, 13]. Previousstudies found the mutation in 17%–65% of anaplastic PXA [4, 14, 15]. However, there is no definitive BRAF V600E mutation status in anaplastic PXA or in conventional PXA. In addition, its clinical value is yet to be established.

It is well known that the efficacy of TMZ is related to the promoter methylation of MGMT [16]. To assess the clinical application value of TMZ for aggressive PXA, G. Marucci et al. [17] examined the MGMT methylation status in 9 PXA patients and 2 anaplastic PXA patients. They found that only 2 PXA patients presented with MGMT promoter methylation. Others, including 2 anaplastic PXA cases, were found to be unmethylated. In another study, Martínez et al. [18] investigated the differences in DNA methylation alterations between conventional PXA and anaplastic PXA. They found that promoter hypermethylation of HOXA5, CD81, ASCL2, HCK and TES genes in anaplastic PXA cases was comparable to that in conventional PXA [18]. However, all these findings need to be confirmed in larger sample based studies to identify clinically relevant biomarkers and guide treatment of anaplastic PXA.

Maximal surgical resection is considered to be the first choice for the treatment of anaplastic PXA. However, the available treatment options following surgical resection have not been adequately investigated. The efficacy of the standard regimen of adjuvant chemotherapy or radiotherapy has not been established on account of the rarity of anaplastic PXA.

A review of published literature reveals that some chemotherapeutic regimens have been used with different degrees of effectiveness, such as vincristine and carboplatin, and TMZ. In our case, we decided to use concurrent TMZ with radiotherapy due to the diffuse growth pattern and the presence of residual tumor. Unfortunately, the tumor recurred and disseminated to distant regions even though TMZ was continuously used and cisplatin was added. Consistent with the results reported by Marucci et al. [17], we also raise doubts about the benefits of TMZ in the treatment of anaplastic PXA. Chamberlain et al. [19] assessed the toxicity and response of vemurafenib, a BRAF inhibitor, in 4 adults with recurrent PXA having BRAF V600E mutation. Vemurafenib appeared to show a single agent activity with acceptable toxicity [19]. However, definitive evidence of its efficacy is yet to be obtained.

Conclusions

We report a case of anaplastic PXA which is difficult to manage. Although the clinical course of PXA has been acknowledged as being benign, the probability of dissemination, early recurrence, and malignant progression should be noted. Standardized treatment strategy for anaplastic PXA has not been established owing to the rarity of the disease. Based on our summarization, early diagnosis and aggressive treatment appears to be the best strategy in these patients.

Abbreviations

FDG: 

18F–fluorodeoxyglucose

GFAP: 

glial fibrillary acidic portein

MET: 

11C–methionine

MGMT: 

O-6-methylguanine DNA methyltransferase

MRI: 

Magnetic Resonance Imaging

PET-CT: 

Positron emission tomography–computed tomography

PXA: 

Pleomorphic xanthoastrocytoma

TMZ: 

Temozolamide

Declarations

Acknowledgements

Not applicable.

Funding

We thank grants from the the National Natural Science Foundation of China (no. 81472352) and the Specialized Research Fund for the Doctoral Program of Higher Education (no. 20131202110006). Both of the two fundings were based on the comprehensive therapy of glioma.

Availability of data and materials

All the data we needed was presented in the main paper.

Authors’ contributions

XY and JS conceived the project and designed the study. MZ and CZ collected patient’s data. CS, SY, YF and WY provided technical assistance in the study. KZ and LW prepared the illustration. MZ and CZ analyzed data and wrote the paper. All authors approved the paper for the submission.

Ethics approval and consent to participate

Not applicable.

Consent for publication

The patient’ father provided his kind permission for the publication of this report and any accompanying images, and the written informed consent was provided.

Competing interests

The authors declare that they have no competing interest.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurosurgery, Affiliated Hospital of Qingdao University
(2)
Department of Neurosurgery, Tianjin Medical University General Hospital
(3)
Department of Neurosurgery, Affiliated Hospital of Logistics University of People’s Armed Police Force
(4)
Department of Neurosurgery, Cangzhou Central Hospital
(5)
Department of Neuropathology, Tianjin Neurological Institute, Tianjin Medical University General Hospital

References

  1. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer. 1979;44(5):1839–52.View ArticlePubMedGoogle Scholar
  2. Giannini C, et al. Pleomorphic xanthoastrocytoma: what do we really know about it. Cancer. 1999;85(9):2033–45.View ArticlePubMedGoogle Scholar
  3. Fouladi M, et al. Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro-Oncology. 2001;3(3):184–92.PubMedPubMed CentralGoogle Scholar
  4. Schmidt Y, et al. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. J Neuro-Oncol. 2013;111(1):59–69.View ArticleGoogle Scholar
  5. Koga T, et al. Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro-Oncology. 2009;11(4):446–51.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Benjamin C, et al. Anaplastic pleomorphic xanthoastrocytoma with spinal leptomeningeal spread at the time of diagnosis in an adult. J Clin Neurosci. 2015;22(8):1370–3.View ArticlePubMedGoogle Scholar
  7. Okazaki T, et al. Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis--a pediatric case report and review of the literature. J Neuro-Oncol. 2009;94(3):431–7.View ArticleGoogle Scholar
  8. Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.View ArticlePubMedGoogle Scholar
  9. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Hirose T, et al. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types. Histopathology. 2008;52(2):183–93.View ArticlePubMedGoogle Scholar
  11. Lubansu A, et al. Cerebral anaplastic pleomorphic xanthoastrocytoma with meningeal dissemination at first presentation. Childs Nerv Syst. 2004;20(2):119-22.Google Scholar
  12. Bayindir C, et al. Anaplastic pleomorphic xanthoastrocytoma. Childs Nerv Syst. 1997; 13(1):50-6.Google Scholar
  13. Dougherty MJ, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-Oncology. 2010;12(7):621–30.Google Scholar
  14. Schindler G, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–05.Google Scholar
  15. Dias-Santagata D, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6(3):e17948.Google Scholar
  16. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.Google Scholar
  17. Marucci G, Morandi L. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. J Neuro-Oncol. 2011;105(2):397–400.Google Scholar
  18. Martinez R, et al. DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma. BMC Cancer. 2014;14:213.Google Scholar
  19. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol. 2013;114(2):237–40.Google Scholar

Copyright

© The Author(s) 2017

Advertisement